false
0001768224
0001768224
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date
of earliest event reported): November 16, 2026
ARCTURUS THERAPEUTICS
HOLDINGS INC.
(Exact name of registrant
as specified in its charter)
| Delaware |
|
001-38942 |
|
32-0595345 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
10285 Science Center
Drive
San Diego, California
92121
(Address of principal
executive offices)
Registrant’s
telephone number, including area code: (858) 900-2660
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common stock, par value $0.001 per share |
|
ARCT |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
Securities Purchase Agreement and Registration Rights Agreement
On November 16, 2026, Arcturus Therapeutics Holdings
Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Meiji Seika
Pharma Co., Ltd. (“Meiji”). Pursuant to the terms of the Purchase Agreement, the Company sold to Meiji an aggregate of 2,466,395
shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), for an aggregate purchase
price of $50.0 million. The purchase price represents a premium of 80% to the average closing price of the Common Stock over the
30 trading days through and including November 11, 2026. If the Company and Meiji do not enter into a definitive license agreement contemplated
by the MOU (as defined below) by May 31, 2027, the Company is required to refund to Meiji 50% of the premium, or approximately $11.1 million,
payable in cash or, at the Company’s election and subject to certain limitations, shares of Common Stock.
Pursuant to the Purchase Agreement, for a period
of 24 months following the closing of the transactions contemplated by the Purchase Agreement, which occurred concurrently with its execution,
(i) Meiji agreed to customary standstill provisions, including a prohibition on acquiring securities of the Company that would result
in Meiji and its affiliates beneficially owning more than 9.9% of the outstanding Common Stock, and (ii) the Company granted Meiji the
right to participate in certain future issuances of equity securities by the Company, subject to a 9.9% ownership limitation. In addition,
Meiji agreed not to offer, sell, pledge, hedge or otherwise transfer or dispose of the Shares through the 365th day following the date
of the Purchase Agreement. The standstill provisions, participation right and transfer restrictions are each subject to certain limited
customary exceptions. The Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.
In connection with the Purchase Agreement, the
Company and Meiji entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the Registration
Rights Agreement, the Company agreed to file a registration statement on Form S-3 (or another appropriate form if Form S-3 is not available)
providing for the resale by Meiji of the Shares no later than the earlier of (i) the 180th day following the closing and (ii) the 30th
day following any early termination of, or the Company’s consent to a disposition under, the transfer restrictions described above,
and to use commercially reasonable efforts to cause such registration statement to be declared effective no later than the earlier of
(a) the 90th calendar day following its filing if the Securities and Exchange Commission notifies the Company that it will review the
registration statement and (b) the fifth trading day after the Company is notified that the registration statement will not be reviewed
or will not be subject to further review. The Company also agreed to use commercially reasonable efforts to keep such registration statement
continuously effective until the registered shares have been sold or may be sold without restriction under Rule 144 under the Securities
Act of 1933, as amended (the “Securities Act”).
Copies of the Purchase Agreement and Registration
Rights Agreement will be filed as exhibits 10.1 and 10.2 to the Company’s Annual Report on Form 10-K for the year ended December
31, 2026 and are incorporated into this Item 1.01 by reference. The foregoing descriptions of such agreements are qualified in their entirety
by reference to the full text thereof.
Collaboration Documents
Concurrently with the Purchase Agreement, Arcturus
Therapeutics, Inc., a wholly owned subsidiary of the Company (“Arcturus”), and Meiji entered into a license agreement relating
to the application of ARCT-154 technology for an undisclosed therapeutic area. Meiji will be responsible for development and commercialization
at its cost.
The Company and Meiji also entered into a non-binding
memorandum of understanding (the “MOU”), which sets forth the principal terms on which the parties will negotiate a definitive
agreement under which the Company would grant Meiji an exclusive license to its self-amplifying mRNA and lipid nanoparticle technologies
for pandemic preparedness and response in Japan. Neither party is obligated to enter into such definitive agreement.
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth in Item 1.01 of this Current Report on Form
8-K under the heading “Securities Purchase Agreement and Registration Rights Agreement” is hereby incorporated by reference
into this Item 3.02 in its entirety. The issuance and sale of the Shares has not been registered under the Securities Act. The Shares
were sold in reliance on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof. None
of the Shares may be offered or sold in the United States absent registration or an applicable exemption from registration. This Current
Report on Form 8-K is not an offer to sell or the solicitation of an offer to buy any securities.
Item 7.01 Regulation FD Disclosure.
On November 16, 2026, the Company issued a press
release regarding the transactions with Meiji. A copy of the press release is furnished as Exhibit 99.1 to this report. The information
in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any
filing with the Securities and Exchange Commission, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description of Exhibit |
| 99.1 |
Press Release, dated November 16, 2026 |
| 104 |
Cover Page to this Current Report on Form 8-K in Inline XBRL |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
Arcturus Therapeutics Holdings Inc. |
| Date: November 16, 2026 |
|
| |
|
|
| |
By: |
/s/ Joseph E. Payne |
| |
Name: |
Joseph E. Payne |
| |
Title: |
Chief Executive Officer |
Arcturus Therapeutics Announces $50 Million
Investment by Meiji Seika Pharma as Part of Expanded Collaboration
$50 Million Strategic Investment in Arcturus
at an 80% Premium
Proceeds to accelerate development of ARCT-2601
for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform
SAN DIEGO--(BUSINESS WIRE) -- November 16, 2026
-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines
company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma
Co., Ltd. (“Meiji”), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum
of understanding (“MOU”) related to pandemic preparedness and response in Japan and an exclusive license relating to the application
of Arcturus’ ARCT-154 technology for an undisclosed therapeutic area.
Under the terms of the securities purchase agreement, Meiji will purchase
$50 million of unregistered Arcturus securities at a purchase price of $20.27 per share, which is 7.9% of the outstanding shares of
Arcturus after the transaction.
Concurrent with the execution of the securities
purchase agreement, Arcturus and Meiji entered into an exclusive license agreement relating to the application of ARCT-154 technology
for an undisclosed therapeutic area, and a Memorandum of Understanding (MOU) establishing the principal terms for a potential collaboration
and license agreement for a pandemic preparedness and response program in Japan using the Arcturus platform.
“We are pleased to expand our relationship
with Meiji as we advance innovative mRNA medicines and seek to deliver value to patients. The investment, together with the license agreement
and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology
platform,” said Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics. “Alongside our CF program, these
proceeds will be used to accelerate development of ARCT-2601 for OTC deficiency, the first mRNA therapeutic to utilize our LUNAR 2.0™
delivery platform.”
About Arcturus
Founded in 2013 and based
in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused
on the development of liver and respiratory therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR®
mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®,
the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus’ strategic collaborations
include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a
Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes programs in cystic fibrosis
(CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus’ versatile RNA therapeutics platforms
can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense
RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio
(over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information,
visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
About
Meiji Seika Pharma
Meiji
Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including
therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and hematologic disorders and generic
drugs, to meet various medical needs. The company continues to advance global health by investing in next-generation innovation and strategic
cross-border partnerships.
https://www.meiji.com/global/pharmaceuticals/
Forward Looking Statements
This
press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press
release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of the Company’s
pipeline (including ARCT-032, ARCT-810 and ARCT-2601), the use of the proceeds from the investment in Arcturus, the likelihood of and
timing for development of ARCT-2601 and for the clinical validation of LUNAR 2.0, the likelihood of and timing for entering into a definitive
agreement based on the Memorandum of Understanding, and the impact of general business and economic conditions. Arcturus may not actually
achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as
the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions
or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form
10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except
as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which
speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com